Cepheid (CPHD) Price Target Raised to $52.00 at Barclays PLC

Danaher Corporation (NYSE:DHR) have shown a high EPS growth of 7.70% in the last 5 years and has earnings growth of -5.50% yoy. The analysts estimated sales for the higher end at 161 million and lower end at 149 million while the year ago reported sale was 158.16 million. The shares were sold at an average price of $36.71, for a total value of $27,385.66.

A pair of USA -based 3-D printing companies traded higher after General Electric made a big bet on the industry. 0 analysts have suggested “Sell” for the company.

The news comes two months after the life-science instrument giant completed the spinoff of its industrial technology and testing unit, Fortive Corporation FTV. Credit Suisse Group AG reiterated a “hold” rating on shares of Danaher Corp.in a research report on Sunday, May 29th. A number of other analysts have commented on the stock recently, and Cepheid has earned a consensus one-year price target of $46.96, lower than the opening price of $52.43, a difference of 8.92 percent.

While a ho-hum deal for investors who like more near-term accretion, we expect that BioProduction will drive near-term organic beats and the current share price is a good entry point to add shares. On Aug 30, 2016 the shares registered one year high at $82.64 and the one year low of $61.60 was seen on Jan 26, 2016.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.16 per share according to consensus of 16 analysts.

Following previous ticker characteristics, Chicago Bridge & Iron Company N.V. (NYSE:CBI) also run on active notice, stock price moved down -0.20% after traded at $29.51 in most recent trading session. Similarly, the company’s last 5 years high P/E ratio is 874.24 and low P/E is 874.24, whereas, the industry’s and sector’s high P/E for the past year is 73.03 and 43.69 respectively and low P/E ratio for the last 5 years is 23.45 for the industry and 20.01 for the Sector. The 12-month average price target assigned to the stock is $40.33, which implies an upside of 17.2% from current levels. Also, the Hold rating count is 9 as of 9/6/2016. Finally, Canaccord Genuity restated a “hold” rating and set a $32.00 target price on shares of Cepheid in a report on Wednesday, June 29th.

Sunnyvale, CA-based Cepheid develops molecular systems for genetic testing.

Under the terms of the merger agreement, Danaher will acquire all of Cepheid’s outstanding stock for $53.00 per share, a 54 percent premium to Friday’s close. Cowen and Company lowered Cepheid from an outperform rating to a market perform rating in a research report on Wednesday.

“We expect Cepheid to be an excellent complement to our existing Diagnostics businesses and to expand our runway for growth across the platform”.